Donor-derived cell-free DNA (dd-cfDNA): An established biomarker for allograft injury.

• It is fragmented DNA in the bloodstream that originates from cells undergoing cell injury and death.
• It is a minimally invasive biomarker for organ transplant surveillance.



When graft injury occurs, dd-cfDNA levels increase in blood.







dd-cfDNA provides a real-time assessment of allograft status




From graft quiescence to rejection and through recovery, AlloSeq cfDNA enables personalized and timely clinical decision‑making.

AlloSeq cfDNA: dd-cfDNA solution for allograft injury surveillance

Targets 202 bi-allelic SNPs across 22 autosomes Test up to 24 samples/run Combinable with other AlloSeq protocols in one sequencing run Validated on Illumina MiniSeq, MiSeq, (MiSeq i100 Series)

No prior genotyping required From cfDNA sample to reported result in up to 24 hours with up to 1.5 hours hands-on time Analytically and clinically validated by multi-center studies




AlloSeq cfDNA provides an accurate, less invasive, solution to surveilling allograft injury



• Minimally invasive compared to biopsy.
• Demonstrated ability to help detect early injury and rejection when combined with standard of care.